Clinical and regulatory intelligence for Anxiety Disorders with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Relevant assets

FDA →

Neurovalens →

Relevant companies

No related entities indexed yet.

Recent signals(2)

ClinicalJuly 5, 2026

Neurovalens Initiates VeNS Trial for Adolescent Anxiety Treatment

Neurovalens Ltd. is conducting a randomized trial to assess the efficacy of Electrical Vestibular Stimulation for Generalized Anxiety Disorder in adolescents.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Buspirone Hydrochloride ANDA075388 by Oxford Pharms

The FDA has granted an Abbreviated Approval (AP) status for the ANDA075388 application for Buspirone Hydrochloride submitted by Oxford Pharms.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Anxiety Disorders →

Mental Health →

Neurology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.